Hypera (HYPE3.SA) Saham Harga
Hypera Harga
Selama 19 tahun terakhir pendapatan Hypera tumbuh 17,2% per tahun, mencapai 7,70 miliar BRL. Laba per saham tumbuh 15,8% per tahun selama 18 tahun terakhir. Bagi Hypera, margin bersih sebesar 15,5% turun dibanding 22,4% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 5,45%. Rasio pembayaran sekitar 63% dari laba. Dividen tumbuh 17,6% per tahun selama 14 tahun terakhir. Target harga konsensus 12 bulan untuk Hypera adalah 30,09 BRL, sekitar di atas harga saat ini 40,3%. Dari 19 analis, 13 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Hypera
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Hypera
Pertanyaan yang sering diajukan tentang saham Hypera
Hypera SA, a leading pharmaceutical company based in Brazil, operates on a robust business model. The core of their business involves the manufacturing, marketing, and distribution of a wide range of pharmaceutical products. Hypera SA specializes in both prescription and over-the-counter medications, catering to various therapeutic areas. They also produce medical-hospital products and non-pharmaceutical items such as personal hygiene and beauty care products. With a focus on innovation and quality, Hypera SA aims to improve the health and well-being of individuals across the country. As a prominent player in the pharmaceutical industry, Hypera SA continues to expand its product portfolio, enhance operational efficiency, and ensure customer satisfaction.
Hypera SA is primarily active in the pharmaceutical industry.
The main competitors of Hypera SA in the market are pharmaceutical companies such as Aché Laboratórios, EMS Pharma, and Eurofarma.
Hypera SA, formerly known as Hypermarcas SA, is a leading pharmaceutical company based in Brazil. Founded in 2001, Hypera has a rich history and has significantly grown over the years. It focuses on the development, production, and commercialization of pharmaceutical products, generic drugs, over-the-counter medications, and personal care items. Hypera has established a strong presence in the Brazilian market, offering a wide range of high-quality and affordable healthcare solutions. Its commitment to research and innovation has led to numerous successful product launches. Hypera SA continues to be a prominent player in the pharmaceutical industry, continuously expanding its portfolio and enhancing the well-being of consumers.
Hypera SA, a renowned company in the pharmaceutical industry, has accomplished several significant milestones throughout its journey. The company has successfully positioned itself as a leader in the Latin American market, expanding its presence across various countries. Hypera SA has consistently demonstrated its commitment to innovation and research, introducing numerous breakthrough pharmaceutical products. With strategic acquisitions and partnerships, the company has further strengthened its portfolio and market share. Hypera SA's relentless focus on quality control and strict adherence to regulatory standards has earned it a stellar reputation among industry experts and stakeholders. These achievements reflect Hypera SA's dedication to advancing healthcare solutions and driving long-term growth in the pharmaceutical sector.
Hypera SA is primarily present in Brazil.
Hypera SA represents a strong commitment to its corporate philosophy, which revolves around innovation, excellence, and integrity. With a focus on enhancing quality of life, Hypera SA aims to deliver innovative healthcare solutions to consumers. The company puts a strong emphasis on research and development, constantly striving to introduce new and effective products to market. By promoting a culture of excellence, Hypera SA seeks to provide top-notch customer service and quality-assured products. With a dedication to integrity, the company operates transparently and ethically, ensuring trust and reliability among its stakeholders. Hypera SA's values and corporate philosophy ultimately drive its mission to positively impact people's health and well-being.
Analis saat ini menetapkan target harga rata-rata 30,54 BRL untuk saham Hypera (median: 30,09 BRL), yaitu +42,4 % terhadap harga terbaru. Konsensus didasarkan pada 19 peringkat analis.
19 analis saat ini menilai saham Hypera: 13 merekomendasikan beli, 6 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Hypera menghasilkan pendapatan 9,23 miliar BRL dan laba per saham 2,65 BRL.
Dengan kurs saat ini, saham Hypera diperdagangkan pada 3,60 EUR (21,45 BRL).
Saham Hypera (HYPE3.SA) tercatat di 2 bursa, termasuk: B3 (São Paulo) (HYPE3.SA).
The Brazilian company Hypera SA is a leading manufacturer and distributor of pharmaceuticals, dietary supplements, cosmetics, and household products. It has been listed on the stock exchange since 2008 and has built a strong presence in the Brazilian market in recent years. Hypera SA operates in four business segments: Consumer Health, Pharma, Over-the-Counter medicines, and Cosmetics and Skincare products. The Consumer Health division offers a wide range of products such as vitamins, pain relievers, cough and cold medicines, as well as dietary supplements and baby food. Hypera SA's Pharma business includes prescription drugs, including medications for cardiovascular, diabetes, gastroenterology, and oncology patients. Additionally, the company also provides vaccines and medications for respiratory diseases. In the Over-the-Counter medicines segment, the company offers a wide range of non-prescription medications for colds, digestive issues, pain, and allergies. This includes diet and weight loss products, vitamins and minerals, as well as other supplements. Hypera SA also offers a variety of cosmetic and skincare products, including brands like Episol, Hair Fly, Monange, Neostrata, and Assolan. The company also operates a household products division, which includes brands like Vitasay, Tixan, and Blergh. The product range of Hypera SA is diverse, ranging from affordable mass-market products to more expensive premium brands. The company aims to reach a wide range of customers and has specialized in marketing products for the health and beauty segment. It has established relationships with major retail chains as well as pharmacies and other sales locations. Hypera SA strives to integrate innovation and technology into its business model. The company has a research and development team constantly developing and launching new products. It also invests in automation and digitization of its production facilities to improve the efficiency and quality of its products. Overall, Hypera SA's business model is focused on a wide product range and a strong brand presence. The company relies on price competition and innovation to strengthen its market position. As a leading provider of healthcare, cosmetic, and household products in Brazil, the company aims to expand internationally.
Pendapatan diperkirakan dari Hypera adalah 9,23 miliar BRL. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Hypera adalah 1,70 miliar BRL. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Hypera saat ini adalah 8,10. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Hypera.
Rasio harga-terhadap-penjualan (PSR) Hypera saat ini adalah 1,49. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Hypera.
Skor Kualitas AlleAktien untuk Hypera adalah 6/10.
ISIN dari Hypera adalah BRHYPEACNOR0. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
Ticker dari Hypera adalah HYPE3.SA. Simbol ticker digunakan untuk memperdagangkan saham Hypera di bursa saham.
Saham Hypera
Semua metrik fundamental dan analisis mendalam Hypera
Analisis saham kami untuk saham Hypera mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Hypera. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.